We’re delighted to share that the EpilepsyMeds app has been shortlisted as a finalist at the Excellence in Healthcare Partnership Awards 2026, in the category Partnership Team of the Year (Pharmaceuticals).
EpilepsyMeds is a three-way partnership between Desitin Pharma, ChangeMed, and Genetic Digital, created to support safer, more confident clinical decision-making in epilepsy care. The mobile-first app gives healthcare professionals fast, reliable access to licensed anti-seizure medicines information, including formulations, excipients and direct links to SmPCs — all designed for use at the point of care.
The shortlist recognition reflects the strength of the collaboration and the real-world impact the app is having across UK clinical practice. Since launch, EpilepsyMeds has been widely adopted by epilepsy specialists and has received strong endorsement from clinicians and patient organisations.
The awards ceremony will take place on 5th February 2026 in London. We’re hugely proud of everyone involved and look forward to celebrating the partnership and its impact.